UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2027-2039

2018

Volltextzugriff (PDF)

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors

Expert review of anticancer therapy, 2018-01, Vol.18 (1), p.71-80

2018

Volltextzugriff (PDF)

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance

Frontiers in immunology, 2020-07, Vol.11, p.1479-1479

2020

Volltextzugriff (PDF)

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly

Current oncology reports, 2021-10, Vol.23 (10), p.119, Article 119

2021

Volltextzugriff (PDF)

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Journal of clinical oncology, 2015-03, Vol.33 (8), p.910-915

2015

Volltextzugriff (PDF)

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2895-2902

2013

Volltextzugriff (PDF)

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

PloS one, 2017-04, Vol.12 (4), p.e0175679-e0175679

2017

Volltextzugriff (PDF)

The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation

Current medicinal chemistry, 2024-01, Vol.31 (21), p.3043-3056

2024

Volltextzugriff (PDF)

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

Journal of clinical oncology, 2012-05, Vol.30 (14), p.1692-1698

2012

Volltextzugriff (PDF)

ALK inhibitors in the treatment of advanced NSCLC

Cancer treatment reviews, 2014-03, Vol.40 (2), p.300-306

2014

Volltextzugriff (PDF)

The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients

Current oncology (Toronto), 2024-02, Vol.31 (2), p.987-997

2024

Volltextzugriff (PDF)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2433

2023

Volltextzugriff (PDF)

Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy

Expert opinion on pharmacotherapy, 2016-03, Vol.17 (4), p.561-570

2016

Volltextzugriff (PDF)

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

The lancet oncology, 2014-10, Vol.15 (11), p.1254-1262

2014

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

The lancet oncology, 2015-09, Vol.16 (9), p.1071-1078

2015

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

The lancet oncology, 2015-09, Vol.16 (9), p.1079-1089

2015

Volltextzugriff (PDF)

Meet the Editorial Board Member

Current medicinal chemistry, 2022-09, Vol.29 (30), p.5041-5041

Gridelli, Cesare

2022

Volltextzugriff (PDF)

The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer

Expert opinion on biological therapy, 2021-03, Vol.21 (3), p.303-309

2021

Volltextzugriff (PDF)

The Potential Role of mTOR Inhibitors in Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2008-02, Vol.13 (2), p.139-147

2008

Volltextzugriff (PDF)

Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application

Therapeutic Advances in Medical Oncology, 2015-09, Vol.7 (5), p.263-273

2015

Volltextzugriff (PDF)

1 – 25 von 478

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(413)
Mit Volltextzugriff
(367)

Publikationsform

Sprache

Englisch
(475)
Italienisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(373)
Life Sciences & Biomedicine
(371)
Humans
(331)
Oncology
(284)
Lung Neoplasms - Drug Therapy
(244)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(223)
Aged
(156)
Female
(132)
Male
(132)
Lung Neoplasms - Pathology
(129)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(106)
Chemotherapy
(105)
Middle Aged
(101)
Antineoplastic Agents - Therapeutic Use
(98)
Carcinoma, Non-Small-Cell Lung - Pathology
(98)
Biological And Medical Sciences
(94)
Medical Sciences
(93)
Respiratory System
(82)
Nsclc
(81)
Adult
(75)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors

Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

ALK inhibitors in the treatment of advanced NSCLC

The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes

Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

Meet the Editorial Board Member

The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

The Potential Role of mTOR Inhibitors in Non‐Small Cell Lung Cancer

Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application

Suchergebnisse filtern